Co-authors of the study, «Sirolimus (SRL) Blunts Mitogen Response at Trough (C0) Levels More Than Cyclosporin (CSA) or Tacrolimus (TAC): A Safeguard for Our Many Long Term
Noncompliant Kidney Transplant Patients (KTPs)» include UC San Diego School of Medicine physicians Nitin Khosla M.D., and Rodolfo Batarse, M.D., assistant professor of medicine.